Latest News for SCNLF
Scancell Holdings plc (SCNLF) Q2 2026 Earnings Call Transcript
Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF, FRA:SCP) confirmed plans to launch a global Phase III trial of its lead cancer immunotherapy, iSCIB1+, as it posted interim results showing a strong balance sheet for current and imminent clinical developments. The company reported a narrowed operating loss of £8.9 million for the six months to 31 October 2025, with cash levels standing at £8.6 million at the end of…
Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF, FRA:SCP) confirmed plans to launch a global Phase III trial of its lead cancer immunotherapy, iSCIB1+, as it...
7.18am: FTSE 100 called higher The FTSE 100 has been called higher as stocks continue to find their footing in what one analyst optimistically called the...
Starbucks Corp (NASDAQ:SBUX, XETRA:SRB) will report its fiscal first quarter earnings on Wednesday, with investors watching closely for signs the coffee...
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for SCNLF.
Senate Trading
No Senate trades found for SCNLF.
U.S. House Trading
No House trades found for SCNLF.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.